[Treatment of complications induced by chemotherapy of acute leukemias].
D000380:Agranulocytosis / Q000139:chemically induced; D000741:Anemia, Aplastic / Q000139:chemically induced; D000900:Anti-Bacterial Agents / Q000627:therapeutic use; D000970:Antineoplastic Agents / Q000009:adverse effects* / Q000627:therapeutic use; D001215:Asparaginase / Q000009:adverse effects; D001792:Blood Platelets; D001803:Blood Transfusion; D003561:Cytarabine / Q000009:adverse effects; D003630:Daunorubicin / Q000009:adverse effects; D004359:Drug Therapy, Combination; D006470:Hemorrhage / Q000209:etiology; D006801:Humans; D007945:Leukemia, Lymphoid / Q000188:drug therapy*; D015470:Leukemia, Myeloid, Acute / Q000188:drug therapy*; D007962:Leukocytes; D015122:Mercaptopurine / Q000009:adverse effects; D008727:Methotrexate / Q000009:adverse effects; D011241:Prednisone / Q000009:adverse effects; D013921:Thrombocytopenia / Q000139:chemically induced; D014750:Vincristine / Q000009:adverse effects
D000900:Anti-Bacterial Agents; D000970:Antineoplastic Agents; D003561:Cytarabine; D014750:Vincristine; D015122:Mercaptopurine; D001215:Asparaginase; D011241:Prednisone; D008727:Methotrexate; D003630:Daunorubicin
Traitement des complications induites par la chimiothérapie des leucémies aiguës